Skip to main content

Rare Mitochondrial DNA Mutation

Successful birth after preimplantation genetic testing for rare mitochondrial DNA mutation m.10197G>A


Here we report the first successful birth after preimplantation genetic testing for m.10197G>A mutation, a rare variant responsible for Leigh encephalopathy. Preimplantation genetic testing diagnosed the embryo with a mutant load of <5%, and transfer resulted in a live birth. The mutant load of embryos diagnosed in this case was skewed to the extremes. Skewed segregation patterns have been observed in common mutations, but this case suggests that the same phenomenon may be seen in this rare mutation.

Mitochondrial DNA (mtDNA) disorders are usually heteroplasmic, with cells harboring both wild-type and mutated mtDNA. They may become apparent once the number of affected mitochondria reaches a certain level. The threshold varies from tissue to tissue, and the percentage level of mutant mtDNA (mutant load, ML) also varies between and within individuals, making it difficult to establish a diagnosis. This is why there is no curative treatment currently available. A great deal of attention has been focused on the field of assisted reproductive technology, and preimplantation genetic testing (PGT) has emerged as an effective preventive option to identify embryos with MLs below disease-causing thresholds.

Not all mtDNA disorders are suitable for PGT, but studies on some of the common mtDNA mutations have shown a correlation between mtDNA heteroplasmy levels in the blastomeres and those in tissues throughout embryo–fetal development. Successful cases of PGT for these mutations, especially m.8993T>G mutation, have been reported to lead to the birth of a healthy baby.

The m.10197G>A mutation (NC_012920.1:m.10197G>A) is a rare pathogenic mutation of Leigh encephalopathy (LE). In a report of three different families with m.10197G>A, all affected children had severe LE with onset in infancy, with most dying within the first 1–2 years of life. Studies on Japanese patients with LE have reported the rarity of this variant in Japan and that LE in MT-ND3 gene is often severe. Here, we report the first successful PGT performed for the m.10197G>A mutation.

A 32-year-old female carrier of the m.10197G>A mutation in the MT-ND3 and her husband requested PGT to fulfill their desire for a healthy child. Their son (proband) was born at term following an uneventful pregnancy of healthy unrelated parents. From soon after birth, he had feeding difficulties and weight gain was poor. Psychomotor retardation became apparent by 4 months, and at 6 months of age, he was hospitalized for respiratory insufficiency. LE was suspected from these symptoms, and analysis of mtDNA mutation was carried out using peripheral blood. The results confirmed homoplasmy of a point mutation in the ND3 region, and a genetic diagnosis of LE was made. He died 7 months after birth owing to LE. The ML of the son and the mother was >99% and 11%, respectively. . After thorough genetic counseling for alternative methods of reproduction including PGT, informed consent was obtained. The study was approved by both ethical committees of the institute and Japan Society for Obstetrics and Gynecology.

gene mutation, point mutation, frameshift mutation, insertion, deletion, missense mutation, nonsense mutation, silent mutation, chromosomal mutation, genetic variation, somatic mutation, germline mutation, mutagenesis, DNA replication error, base pair substitution, genetic disorder, mutation hotspot, oncogene mutation, inherited mutation, spontaneous mutation,

#DNAmutation, #genetics, #molecularbiology, #mutations, #genetherapy, #genomeediting, #CRISPR, #DNAdamage, #genomicinstability, #hereditarydisease, #somaticmutation, #germlinemutation, #cancergenetics, #DNArepair, #pointmutation, #mutationresearch, #geneticvariation, #mutationtypes, #genemutation, #DNAchange

International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

Comments

Post a Comment

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...
Post a Comment
Read more

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...
Post a Comment
Read more

Genetics study on COVID-19

Large genetic study on severe COVID-19 Bonn researchers confirm three other genes for increased risk in addition to the known TLR7 gene Whether or not a person becomes seriously ill with COVID-19 depends, among other things, on genetic factors. With this in mind, researchers from the University Hospital Bonn (UKB) and the University of Bonn, in cooperation with other research teams from Germany, the Netherlands, Spain and Italy, investigated a particularly large group of affected individuals. They confirmed the central and already known role of the TLR7 gene in severe courses of the disease in men, but were also able to find evidence for a contribution of the gene in women. In addition, they were able to show that genetic changes in three other genes of the innate immune system contribute to severe COVID-19. The results have now been published in the journal " Human Genetics and Genomics Advances ". Even though the number of severe cases following infection with the SARS-CoV-...
Post a Comment
Read more